For the quarter ended November 2025, Neogen (NEOG Quick QuoteNEOG - Free Report) reported revenue of $224.69 million, down 2.8% over the same period last year. EPS came in at $0.10, compared to $0.11 in the year-ago quarter.

The reported revenue represents a surprise of +7.13% over the Zacks Consensus Estimate of $209.74 million. With the consensus EPS estimate being $0.07, the company has not delivered EPS surprise.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Neogen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Animal Safety: $59.14 million compared to the $56.56 million average estimate based on three analysts. The reported number represents a change of -11.8% year over year.
• Revenues- Food Safety: $165.55 million versus the three-analyst average estimate of $153.19 million. The reported number represents a year-over-year change of +0.8%.
• Revenues- Food Safety- Indicator Testing, Culture Media & Other: $86.11 million versus $76.36 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +3.4% change.
• Revenues- Animal Safety- Life Sciences: $1.45 million versus $1.6 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -11% change.
• Revenues- Animal Safety- Veterinary Instruments & Disposables: $13.68 million compared to the $15.68 million average estimate based on two analysts. The reported number represents a change of -20.8% year over year.
• Revenues- Animal Safety- Animal Care & Other: $8.89 million versus the two-analyst average estimate of $10.41 million. The reported number represents a year-over-year change of -9%.
• Revenues- Food Safety- Natural Toxins & Allergens: $20.44 million versus the two-analyst average estimate of $19.1 million. The reported number represents a year-over-year change of -0.3%.
• Revenues- Animal Safety- Genomics Services: $17.18 million compared to the $4.83 million average estimate based on two analysts.
• Revenues- Food Safety- Genomics Services: $6.26 million versus the two-analyst average estimate of $13.93 million.
• Revenues- Food Safety- Biosecurity Products: $4.57 million compared to the $8.74 million average estimate based on two analysts.
• Revenues- Food Safety- Bacterial & General Sanitation: $44.92 million versus $39.28 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5.6% change.
• Revenues- Animal Safety- Biosecurity Products: $17.93 million versus $18.7 million estimated by two analysts on average.

View all Key Company Metrics for Neogen here>>>

Shares of Neogen have returned +5.7% over the past month versus the Zacks S&P 500 composite's +0.9% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.